Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371513 | 1.00 | SIGMAR1 (1.00) | SIGMAR1HTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL99116 | 0.99 | SIGMAR1 (0.98) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL467349 | 0.90 | SIGMAR1 (1.00) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL1135405 | 0.90 | SIGMAR1 (0.81) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL1135681 | 0.89 | SIGMAR1 (0.81) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL1135658 | 0.89 | SIGMAR1 (0.81) | SIGMAR1HTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL1894793 | 0.89 | SIGMAR1 (0.98) | SIGMAR1HTR2BKCNH2 | |
| SCHEMBL467090 | 0.89 | SIGMAR1 (1.00) | SIGMAR1HTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL29557756 | 0.89 | SIGMAR1 (0.98) | SIGMAR1HTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL1136301 | 0.89 | SIGMAR1 (0.80) | SIGMAR1HTR2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463339-B1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | ESTEVE PHARMACEUTICALS SA (ES) | 2023-12-06 | — | — | EP | claimed |
| CN-109310672-B | Use of sigma receptor ligands in cancer | 埃斯特韦制药有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-105873580-B | Compositions of gabapentin-like compounds and sigma receptor ligands | 埃斯蒂维制药有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20190142840-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-16 | — | — | US | claimed |
| WO-2019068771-A1 | USE OF SIGMA RECEPTOR LIGANDS IN AGE-RELATED COGNITIVE IMPAIRMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-11 | — | — | WO | claimed |
| EP-3463339-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-10 | — | — | EP | claimed |
| US-RE47214-E1 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2019-01-29 | — | — | US | claimed |
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2019-01-10 | — | — | US | claimed |
| EP-3328365-A1 | USE OF SIGMA RECEPTOR LIGANDS IN DYSLIPIDEMIA | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2018-06-06 | — | — | EP | claimed |
| US-9931346-B2 | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-04-03 | — | — | US | claimed |
| WO-2011064296-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SIGMA RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-03 | — | — | WO | claimed |
| WO-2011064315-A1 | 4-[2-[[5-METHYL-1-(2-NAPHTALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE SALTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-03 | — | — | WO | claimed |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-12 | — | — | US | claimed |
| EP-2292236-A1 | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-03-09 | — | — | EP | claimed |
| EP-2276744-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-01-26 | — | — | EP | claimed |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | claimed |
| US-7696199-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-13 | — | — | US | claimed |
| EP-2116539-A1 | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2009130310-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-29 | — | — | WO | claimed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142840-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885HTR2B 75/4885KCNH2 3544/4885 |
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885HTR2B 40/4885KCNH2 1365/4885 |
| US-20190010128-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885HTR2B 104/4885KCNH2 1308/4885 |
| US-20110112095-A1 | 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF | OPRK1, OPRD1, SIGMAR1 | SIGMAR1 3/4885HTR2B 104/4885KCNH2 1308/4885 |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885HTR2B 40/4885KCNH2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.